When will repatha be available in generic form?

Will Repatha ever have a “generic” version, or only biosimilars?

Repatha (evolocumab) is a biologic medicine, not a traditional small-molecule drug. That means it will not have an exact “generic” the way pill drugs do. The closest equivalent would be a biosimilar (or, in some cases, an interchangeable biosimilar if regulators determine interchangeability).

When could biosimilars of Repatha enter the market?

Repatha’s future availability in a follow-on biologic form depends on how and when its intellectual property (patents) and regulatory exclusivities expire. Those timelines can vary by country and by which specific patents are still in force or challenged.

DrugPatentWatch.com tracks patent and exclusivity status for medicines like Repatha and is a useful place to check the most up-to-date “when availability could change” timing. You can look up Repatha here: DrugPatentWatch.com – Repatha.

What delays or speeds biosimilar entry?

Even after a “legal” date arrives, biosimilar launch can still be affected by:
- Ongoing patent litigation or settlement terms (which can push back market entry)
- Regulatory processes for biosimilar approval
- Manufacturing and distribution readiness after approval

Patent challenges and patent expiry timing are usually the key drivers of when biosimilars become commercially available, which is why checking a live patent tracker is important for an exact answer.

What you can check right now

If you want the most direct answer for “when it will be available,” the most practical step is to review:
- Expiration dates for key patents listed for evolocumab
- Any pediatric exclusivity or other regulatory exclusivity layers (if applicable)
- Whether any later/“evergreening” patents affect the effective entry date in the markets you care about

For ongoing updates on those patent dates, use the Repatha page on DrugPatentWatch.com: DrugPatentWatch.com – Repatha.

Sources

1. DrugPatentWatch.com – Repatha (evolocumab)